Part II: Hodgkin's lymphoma - Diagnosis and treatment

Lancet Oncology

Volumn 5, Issue 1, 2004, Pages 19-26

  Diehl, Volker ^a   Thomas, Roman K ^a   Re, Daniel ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARABINOSIDE; BLEOMYCIN; CARMUSTINE; CD30 ANTIGEN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LOMUSTINE; MELPHALAN; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TUMOR VACCINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON CANCER; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEART MUSCLE INJURY; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFERTILITY; LUNG CANCER; LUNG DISEASE; LUNG FIBROSIS; MALE; MENTAL DISEASE; MORBIDITY; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; REVIEW; RISK ASSESSMENT; SARCOMA; TUMOR BIOPSY; VIRUS INFECTION;

EID: 0347286860     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01320-2     Document Type: Review

References (48)

1. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-6 [erratum in J Clin Oncol 1990; 8: 1602].
2. de Wit M, Bohuslavizki KH, Buchert R, et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.
3. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123-30.
4. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-34.
5. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-14.
6. Noordijk E, Carde P, Hagenbeek A. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials 'H7-VF,' 'H7-F' and 'H7-U'. Int J Radiat Oncol Biol Phys 1997; 39: 173.
7. Sieber M, Frnaklin J, Tesch H, et al. Two cycles ABVD plus extended field radiotherpay is superior to radiotherpay alone in early stage Hodgkin's disease: Results of the German Hodgkin's Lymphoma study group (GHSH) trial HD7. Blood 2002; 100: 341 (abstr).
8. Engert A, Schiller P, Jostig A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherpay in patients with early stage unfavourable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3601-08.
9. DeVita V, Hubbard S. Hodgkin's disease. N Engl J Med 1993; 328: 560-65.
10. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295-306.
11. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104: 739-46.
12. Hancock B. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation. Radiother Oncol 1986; 7: 215-21.
13. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252-59.
14. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002; 346: 1417-18.
15. Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998; 16: 19-26.
16. Duggan DB, Petroni GR, Johnson JL, et al. A randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607-14.
17. Sherins RJ, DeVita VT Jr. Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy. Ann Intern Med 1973; 79: 216-20.
18. Schilsky RL, Sherins RJ, Hubbard SM, et al. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981; 71: 552-56.
19. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316: 710-14.
20. Diehl V. Advanced Hodgkin's disease: ABVD is better, yet is not good enough! J Clin Oncol 2003; 21: 583-85.
21. Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13: 1080-88.
22. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-37.
23. Radford JA, Rohatiner AZS, Dunlop DJ. Preliminary results of a four-centre randomised trial paring weekly VAPEC-B chemotherapy with the ChlVPP/EVA hybrid regimen in previously untreated patients. Proc Am Soc Clin Oncol 1997; 16: 12.
24. Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20: 2988-94.
25. Diehl V. Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG). Ann Hematol 1993; 66: 139-40.
26. Diehl V, Franklin J, Pfreundschuh M, et al. German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-95.
27. Aleman BM, Raemaekers JM, Tirelli U, et al; European Organization for Research and Treatment of Cancer Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396-406.
28. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487-97.
29. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95: 971-80.
30. Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin's lymphoma - a report from the German Hodgkin's Lymphoma Study Group (GHSG). Blood 2000; 96: 1280-86.
31. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221-30.
32. Canellos GP. Treatment of relapsed Hodgkin's disease: strategies and prognostic factors. Ann Oncol 1998; 9 (suppl 5): 91-96.
33. Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol 1998; 9: 289-95.
34. Brice P, Divine M, Simon D, et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol 1999; 10: 1485-88.
35. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-24.
36. Fisher RI, DeVita VT, Hubbard SP, et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90: 761-63.
37. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-18.
38. Bierman PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993; 4: 767-73.
39. Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193-99.
40. Armitage JO, Bierman PJ, Vose JM, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991; 91: 605-11.
41. Gribben JG, Linch DC, Singer CR, et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-44.
42. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-54.
43. Schmitz N, Pfistner B, Sextro M, et al. German Hodgkin's Lymphoma Study Group. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-71.
44. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma - results of a large multicenter study for the prospective randomized HDR-2 trial of the German Hodgkin Lymphoma Study Group (GHSG). Blood 2002; 100: 812 (abstr).
45. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17: 776-83.
46. Rehwald U, Schulz H, Reiser M, et al. German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101: 420-24.
47. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003; 101: 4285-89.
48. Borchmann P, Treml JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003: 102: 3737-42.